Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001GlobeNewsWire • 06/24/22
Valneva Announces Successful Outcome of its AGM and Appointment of two New Supervisory Board MembersGlobeNewsWire • 06/24/22
Valneva announces resumption of trading of its ordinary shares on Euronext ParisGlobeNewsWire • 06/23/22
Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in EuropeGlobeNewsWire • 06/23/22
Valneva SE Sponsored ADR (VALN) Stock Jumps 93.1%: Will It Continue to Soar?Zacks Investment Research • 06/22/22
The Shopify Split Is Just Days Away, but This Tiny Nasdaq Stock Is Soaring Right NowThe Motley Fool • 06/21/22
Pfizer makes equity investment in Valneva as they prepare for Phase 3 trial of Lyme disease vaccine candidateMarket Watch • 06/21/22
Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15Business Wire • 06/20/22
Valneva's stock slides after saying Europe may not order the company's COVID-19 vaccine candidateMarket Watch • 06/13/22
Valneva Provides Update on European Inactivated, Whole-Virus COVID-19 Vaccine Program VLA2001GlobeNewsWire • 06/10/22
Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate, Host Symposium at NECTM8GlobeNewsWire • 06/07/22
Valneva to Present and Hold Investor Meetings at the Jefferies US Healthcare ConferenceGlobeNewsWire • 06/03/22